The 2-year progression-free survival (PFS) was 42% in the donor group and 18% in the no-donor group (P < .0001). The 2-year overall survival (OS) was 54% in the ...
Mar 21, 2022 ˇ Myeloma patients: a large cohort study from Chronic Malignancies Working Party – ... allo-HCT following reduced intensity regimen for ...
... reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.
... reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.
Mar 4, 2024 ˇ Moreover, new drugs have enabled better disease control before alloSCT, thereby improving long-term survival outcomes. AlloSCT may be a ...
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma ... prognostic factors from the Chronic Leukaemia Working Party of the EBMT.
Disregarding if alloSCT was actually carried out or not, survival from the 3-month landmark was significantly better in matches versus controls [hazard ratio ...
Outcomes for Reduced-Intensity Allogeneic Transplantation for Multiple Myeloma: An Analysis of Prognostic Factors From the Chronic Leukaemia Working Party of ...
Outcomes for RIC allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.
Apr 4, 2022 ˇ Multiple myeloma (MM) remains incurable for most patients, despite significant improvements in treatment. For patients under the age of 70 years ...